Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma

Katrine Prætorius, Daniel P. Henriksen, Johannes M. Schmid, Pernille Printzlau, Lars Pedersen, Hanne Madsen, Ehm A. Andersson, Louise Klokker Madsen, Bo L. Chawes

Source: ERJ Open Res, 7 (3) 00306-2021; 10.1183/23120541.00306-2021
Journal Issue: July
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Katrine Prætorius, Daniel P. Henriksen, Johannes M. Schmid, Pernille Printzlau, Lars Pedersen, Hanne Madsen, Ehm A. Andersson, Louise Klokker Madsen, Bo L. Chawes. Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma. ERJ Open Res, 7 (3) 00306-2021; 10.1183/23120541.00306-2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: